why choose us

First received: December 06, 2022

Clinical Trial: Co-administration of CART22-65s and huCART19 for B-ALL

Study Status: Completed

Recruit Status: RECRUITING

Condition: B-cell Acute Lymphoblastic Leukemia

Study Type: INTERVENTIONAL


Official Title: Use of Autologous Anti-CD22 CAR T Cells (CART22-65s) Co-administered With Humanized Anti-CD19 CAR T Cells (huCART19) in Children and Young Adults With Relapsed or Refractory B-ALL

Brief Summary: This study will evaluate the safety and efficacy of administering two CAR T cell products, huCART19 and CART22-65s, in children with advanced B cell Acute Lymphoblastic Leukemia (B-ALL).

Read more